The agency concluded that GLP-1 receptor agonists carry a potential increased risk of the rare optic neuropathy and is adding it to the Warnings and Precautions section of every product's label.
Drs Bryce St. Clair and Behrad Garmsiri explain how they build trust, improve health literacy, and destigmatize future interventions for patients with AMD.